Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: A randomised controlled trial

Lancet

Volumn 353, Issue 9163, 1999, Pages 1469-1475

  Wiktor, Stefan Z ^a,b   Sassan Morokro, Madeleine ^a   Grant, Alison D ^a,c   Abouya, Lucien ^a   Karon, John M ^b   Maurice, Chantal ^a   Djomand, Gaston ^a   Ackah, Alain ^a   Domoua, Kouao ^e   Kadio, Auguste ^e   Yapi, Achy ^e   Combe, Patrice ^d   Tossou, Odette ^a   Roels, Thierry H ^a,b   Lackritz, Eve M ^b   Coulibaly, Doulourou ^f   De Cock, Kevin M ^b   Coulibaly, Issa Malick ^f   Greenberg, Alan E ^a,b  

^a Project RETRO CI Abidjan   (Côte d’Ivoire)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Centre Hospitalier   (Côte d’Ivoire)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^f Institut National d Hygiène Publique   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COTE D'IVOIRE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPTICEMIA; SIDE EFFECT; SKIN DISEASE; UROGENITAL TRACT DISEASE;

EID: 0033135568     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03465-0     Document Type: Article

References (33)

1. Graham NM, Zeger SL, Park LP, et al. The effects on survival of early treatment of human innunodeficiency virus infection. N Engl J Med 1992; 326: 1037-42.
2. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS 1997; 11 (suppl B): S43-54.
3. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7: 1569-79.
4. Grant AD, Djomand G, Smets P, et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d'Ivoire. AIDS 1997; 11: 1357-64.
5. Grant AD, Sidibe K, Domoua K, et al. Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Côte d'Ivoire. Int J Tuberc Lung Dis 1998; 2: 926-34.
6. Abouya YL, Beaumel A, Lucas SB, et al. Pneumocystis carinii pneumonia: an uncommon cause of death in African patients with acquired immunodeficiency syndrome. Am Rev Respir Dis 1992; 145: 617-20.
7. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72.
8. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-82.
9. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults affected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-08.
10. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-57.
11. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998; 317: 625-29.
12. De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992; 268: 1581-87.
13. Colebunders RL, Ryder RW, Nzilambi N, et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am Rev Respir Dis 1989; 139: 535-39.
14. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with negative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-55.
15. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodefiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849-54.
16. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-28.
17. Perriens JH, St Louis ME, Mukadi YD. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-84.
18. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-91.
19. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire. AIDS 1995; 9: 1251-54.
20. Vugia DJ, Kiehlbauch JA, Yeboue K, et al. Pathogens and predictors of fatal septicemia associated with human immunodeficiency virus infection in Ivory Coast, West Africa. J Infect Dis 1993; 168: 564-70.
21. Abouya YL, Coulibaly IM, Wiktor SZ, et al. The Côte d'Ivoire national HIV counseling and testing program for tuberculosis patients: implementation and analysis of epidemiologic data. AIDS 1998; 12: 505-12.
22. National Institute of Allergy and Infectious Diseases, Division of AIDS Regulatory Operations Center. Serious adverse experience reporting manual. Rockville, Maryland: National Institute of Allergy and Infectious Diseases, 1998.
23. De Cock KM, Porter A, Kouadio JC, et al. Rapid and specific diagnosis of HIV-1 and HIV-2 infections: an evaluation of testing strategies. AIDS 1990; 4: 875-78.
24. Nkengasong JN, Maurice C, Koblavi S, et al. Field evaluation of a combination of monospecific ELISAs for the type-specific serodiagnosis of HIV-1 and HIV-2 infections in Abidjan, Côte d'Ivoire. J Clin Microbiol 1998; 36: 123-27.
25. Nkengasong JN, Maurice C, Koblavi S, et al. Evaluation of HIV serologic parallel and serial testing algorithms in Abidjan, Côte d'Ivoire. AIDS 1999; 13: 109-17.
26. Satten GA, Datta S, Williamson JM. Inference based on imputed failure times for the proportional hazards model with interval-censored data. J Am Stat Assoc 1998; 93: 318-27.
27. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353: 1463-68.
28. Martin DM, Sim JCM, Sole GJ, et al. CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 386-91.
29. Gilks CF, Brindle RJ, Otieno LS, et al. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet 1990; 336: 545-49.
30. Anglaret X, Sylla-Koko F, Bonard D, et al. Susceptibilities to cotrimoxazole of pathogens isolated from blood and stool specimens in Abidjan, Ivory Coast, 1994-1996. J Clin Microbiol 1997; 35: 1915.
31. Kariuki S, Gilks C, Corkill J, et al. Multi-drug resistant non-typhi Salmonella in Kenya. J Antimicrob Chemother 1996; 38: 425-34.
32. Mache A, Mengistu Y, Cowley S. Salmonella serogroups identified from adult diarrhoeal out-patients in Addis Ababa, Ethiopia: antibiotic resistance and plasmid profile analysis. East Afr Med J 1997; 74: 183-86.
33. Aseffa A, Gedlu E, Asmelash T. Antibiotic resistance of prevalent Salmonella and Shigella strains in northwest Ethiopia. East Afr Med J 1997; 74: 708-13.